Market Exclusive

AGENUS INC. (NASDAQ:AGEN) Files An 8-K Regulation FD Disclosure

AGENUS INC. (NASDAQ:AGEN) Files An 8-K Regulation FD DisclosureItem 7.01

Regulation FD Disclosure.

On February 17, 2017, the Alliance for Clinical Trials in Oncology (the “Alliance”), a cooperative group of the National Cancer Institute, notified Agenus Inc. that the Alliance’s Data and Safety Monitoring Board (“DSMB”) performed an interim analysis for futility of the Phase II trial of Prophage G-200 (Heat Shock Protein Peptide Complex-96 or HSPPC-96) vaccine in combination with bevacizumab in patients with surgically resectable recurrent glioblastoma multiforme. The interim analysis suggested that the trial is unlikely to demonstrate that the vaccine in combination with bevacizumab will lead to a better survival than bevacizumab as a monotherapy. Therefore, upon the DSMB’s recommendation, the accrual for the trial has been closed.

About AGENUS INC. (NASDAQ:AGEN)
Agenus Inc. (Agenus) is an immuno-oncology company. The Company is engaged in discovering and developing treatments for patients with cancer. Its approaches are driven by platforms and programs, which include antibody discovery platform, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage and AutoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon). The Company has a portfolio of programs in various stages of development, including a series of antibodies in discovery and pre-clinical and clinical development, Prophage vaccine, a Heat Shock Protein (HSP)-based vaccine candidate for a form of brain cancer that has completed Phase II trials, and a number of QS-21 Stimulon-containing vaccine candidates in late stage development. AGENUS INC. (NASDAQ:AGEN) Recent Trading Information
AGENUS INC. (NASDAQ:AGEN) closed its last trading session up +0.03 at 4.54 with 2,131,619 shares trading hands.

Exit mobile version